Introduction
The medical knowledge gained in caring for Jehovah's Witness patients who refuse blood transfusions for religious reasons has given rise to a practice movement that challenges conventional medical thinking and poses important questions about blood usage. Namely, how necessary are transfusions [1]? Are transfusions being administered for good reason [2] or simply because of practice habits and outdated medical conventions [3, 4] ? What are tolerable lower limits of hemoglobin concentrations and safe anemia thresholds [5 ] ? Are outcomes better or worse if transfused blood is withheld (Table 1) [1,6,7 -9 ,10,11,12 -14 , [15] [16] [17] ? What are the competing strategies to transfusions, their usage limitations, and cost-effectiveness [18 ,19] ? These questions and their answers are the basis for bloodless medicine and surgery and, in this review, we discuss the history, rationale, limitations, and critical elements for execution of successful bloodless programs.
History and evolution of bloodless medicine and surgery
The world's population of Jehovah's Witnesses has doubled since the 1980s and presently exceeds 6.3 million [20 ] . Subscribers to this religion strictly interpret Bible passages such as 'You must not eat the flesh with the life, which is the blood still in it' from Genesis Ch. 9 v. 4 (New English Bible) and refusal of blood transfusions is a core value of their faith [21] . Medical and surgical treatment of Jehovah's Witness patients using blood products without their consent violates these beliefs and disregards bodily self-determination rights [22 ] . Withholding transfused blood, however, presents an opposing and similarly emotionally charged dilemma for healthcare teams striving to provide the best possible care. This problem is particularly vexing for trauma and cardiac surgical centers, where 12% [23] and 10-20% [24, 25] of the US blood supply, respectively, is transfused. Orthopedic surgery patients (n ¼ 695) rHuEPO raised Hb levels (P < 0.001) and reduced transfusion requirements (12% versus 46%; P < 0.001) but had no effect on outcomes Randomized open study comparing Hb levels, transfusion requirements and outcomes (time to ambulation, LOS, infection rate) in patients treated with rHuEPO versus no rHuEPO; study also compared outcomes in NT versus T patients.
Compared with NT patients, T patients had longer time to ambulation (3.8 versus 3.1 days; P < 0.001) and longer LOS (12.0 versus 10.2 days; P < 0.001) Engoren et al. [15] Cardiac surgery (n ¼ 1915) Mortality after 5 years Prospective cohort study comparing NT versus T patients RR for T versus NT -1.7 (95% CI 1.4-2.0; P ¼ 0.001) Objectives and rationale for bloodless medicine and surgery
Bloodless medicine and surgery may be defined as a strategy for medical and surgical care that seeks to improve outcomes without the use of allogeneic blood transfusions [27, 28] . Execution of a bloodless medicine program takes a coordinated multidisciplinary team, each member embracing the philosophy that care without reliance on transfused blood is appropriate for all patients, not just those with specific religious convictions or when blood is in critically short supply. Specific objectives of bloodless medicine and surgery programs are to optimize preoperative hemoglobin levels, maximize hematopoiesis and red blood cell (RBC) mass, minimize blood loss during and after surgery, and maximize oxygen delivery to tissues [29] .
Transfusion avoidance to achieve bloodless care is not without limitations. Although the objectives seem straightforward, the required resources (equipment and personnel) have associated costs, and the tasks and decisions being made require expert knowledge of transfusion medicine. For example, acute severe anemia remains problematic and critical limits for tissue oxygenation and tolerable lower limits of hemoglobin concentration remain undefined [5 ,27] . Moreover, bloodless medicine is a relatively novel practice concept in nonJehovah's Witness patients.
Blood conservation techniques and limitations
Rather than one simple solution, bloodless medicine and surgery programs must apply several different approaches, often simultaneously ( Fig. 1) , to address the specific needs of patients [30] . Each techniquebe it preoperative, intraoperative, or postoperative -has the capability of conserving 1-2 units of blood but usually not more than 2 units per patient. As such, the first limitation is encountered [28] . 
Preoperative techniques
Highlights of important techniques are discussed below, but several detailed reviews on the topic are also available [20 ,25-27,29,31,32] .
Preoperative autologous donation
Twenty-five years ago, some geographic regions of the US discovered that nearly 1% of blood units were contaminated with HIV and 0.5% with hepatitis C virus, stirring public interest and a sharp rise in collection and use of autologous blood [33] . Applicable only to elective surgery and limited to procedures such as elective joint replacements, preoperative autologous donation (PAD) typically involves collection of 4 units of whole blood over a 4-week preoperative period [28] . Precollected blood is then stored and reinfused if perioperative, intraoperative, or postoperative transfusion needs arise. This technique has a number of important limitations. First, PAD is not acceptable to Jehovah's Witnesses [20 ] . Second, stored blood has a limited lifespan, and recent studies suggest its useful life may be shorter than the 42 days allowable in US blood banks (Fig. 2) [34] . Third, it may be inconvenient for patients to undergo preoperative visits to blood collection facilities. Fourth, and perhaps most importantly, patients are typically unable to regenerate all of the RBC volume lost in the period between selfdonation and surgery. Thus, the effect of PAD, especially without augmentation of hematopoiesis with erythropoietic agents, is akin to chronic hemodilution [33] .
Neither the efficacy nor cost-effectiveness of PAD has been established, with wasted blood collected for autologous reinfusion adding to storage and handling costs. Moreover, when patients participate in PAD programs, exposure to allogeneic blood is decreased but more overall transfusions are actually administered [35] . Clerical errors and transfusion mishaps are not eliminated and can still pose a problem. For these reasons, widespread use of PAD as a blood conservation strategy is on the decline and currently quite limited. If PAD is to be effective, it should be combined with other techniques and postoperative anemia monitored and managed pharmacologically as necessary [25] .
Increase in red blood cell mass with erythropoietic agents, iron, folate, and B 12
Recombinant human erythropoietin (rHuEPO) has been used successfully to increase hemoglobin and decrease transfusion requirements [14 ,36-40] [41] [42] [43] [44] . To promote effective erythropoiesis and avoid functional iron deficiency and proliferation of microcytic, hypochromic red cells, supplementation with iron, vitamin B 12 , and folate should always accompany the use of rHuEPO [20 ,45] . In randomized, double-blind studies evaluating the use of rHuEPO in critically ill patients, the drug was safe, increased hemoglobin levels, and reduced the need for RBC transfusions but had no effect on mortality [36, 46] . In another study of patients undergoing radical prostatectomy, postoperative anemia was prevented using a combination of rHuEPO plus acute normovolemic hemodilution (ANH) compared with PAD or ANH alone. Allogeneic blood exposure, however, was similar across groups [47] . The cost-effectiveness of using rHuEPO has been questioned [47, 48] but also strongly and appropriately defended by Corwin and Hebert [18 ] , who argue that efforts to ensure the safety of the blood supply are associated with enormous costs far exceeding dollar benchmarks for 'cost-effective' interventions. Despite the ready availability of rHuEPO, its use as an alternative to transfusion is still suboptimal [27] , leaving much room for improvement. Original magnification 2200 Â . Reprinted from Berezina et al. [34] with permission from Elsevier.
Reduce the transfusion trigger
Hebert et al. [7 ] demonstrated in a randomized controlled trial that better outcomes were associated with a restrictive transfusion policy (hemoglobin 7 g/dl) compared with a liberal transfusion policy ( 10 g/dl) in most patients, possibly excepting those with severe cardiac disease. According to a metaanalysis by Carson et al. [49] , reducing the transfusion trigger (i.e. the hemoglobin threshold that 'triggers' transfusion administration) may be the best way to avoid transfusions and incurs no material cost [18 ] . Has this strategy, however, been universally adopted? Studies of transfusion practices conducted after Hebert and colleagues' findings became widely known, however, indicate that transfusion triggers are still too high, with transfusions still being administered at hemoglobin thresholds between 7 and 9 g/dl in one study [50] , between 8 and 9 g/dl in another [51 ] , and with 21% of transfusions given at a hemoglobin threshold of over 10 g/dl in yet another [52] . Reducing transfusion triggers institution-wide requires intensive education, mentoring, and commitment on the part of an integrated team; however, this approach may be well worth the effort [53 ] .
Anemia tolerance
As learned from real experiences with Jehovah's Witness patients and experimental data, a certain degree of shortterm anemia is well tolerated [5 ,6] . Moreover, tolerance to anemia may be improved by maintaining normovolemia with colloid infusions that reduce the likelihood of tissue edema and preserve tissue oxygenation [25] . Exactly how low the hemoglobin threshold of any individual patient can go, however, is difficult to predict and requires individual patient assessment and management based on clinical circumstances. The approach of reducing the transfusion trigger is limited by our current state of knowledge regarding anemia tolerance in all patient populations [54] .
Intraoperative techniques
The importance of controlling blood loss during surgery using advanced and minimally invasive surgical techniques as a means of reducing the need for transfusions cannot be overemphasized [28, 31] .
Meticulous hemostasis and operative techniques
Electrocautery, argon-beam coagulation, heparin-coated tubing to avoid systemic heparinization, tourniquets, local vasoconstriction with epinephrine or other hemostatic agents, and avoidance of hypothermia (affects platelet aggregability) are some techniques that help limit intraoperative bleeding [26, 28, 29, 31] . Surgical planning and preoperative 'rehearsals' increase efficiency and speed that can minimize surgical times and curtail blood loss [29] . In cardiac surgery, off-pump coronary artery bypass graft (CABG) procedures are becoming more widely used and are associated with reduced coagulopathy [55] . These new methods are more difficult technically than traditional on-pump CABG procedures and may require special surgical training [56 ] . Controlled hypotensive anesthesia is another technique that may reduce blood loss, particularly in orthopedic surgery, but is controversial among anesthesiologists who must ensure that major organs like the heart and brain are adequately perfused [28, 31] .
Acute normovolemic hemodilution
Introduced in the 1970s, ANH involves removing a volume of blood from a patient immediately before surgical incision, while simultaneously maintaining normovolemia by infusing an equivalent amount of colloid or crystalloid solution. Colloidal solutions are preferred because they better preserve tissue oxygenation, and crystalloids can result in anemia and an increased need for transfusions [25, 57] . The strategy behind ANH is to lower the mass of RBCs that are shed during operative procedures while preserving the clotting factors [25, 57, 58] . Compared with PAD, ANH is cost-effective [47] , not associated with waste or need for blood storage, involves no transfusion mishaps, and does not require blood to be prescreened for infectious agents [31] . Mixed opinions about the efficacy of ANH exist, however, and questions still remain about its relative safety. Whereas some suggest that ANH is inappropriate for patients with severe hepatic, renal, pulmonary, or coronary artery disease [31] , others report that ANH is safe and effective in patients undergoing a variety of surgical procedures to lower perioperative blood usage [57] . One metaanalysis of 24 randomized clinical trials (RCTs) conducted across a broad range of surgical settings cited flaws in design as a possible explanation for impressive transfusion reductions, noting that when a protocol was used to guide perioperative transfusion, ANH failed to reduce transfusions or the number of RBC units transfused [59] . In a RCT of patients undergoing liver resection, however, Matot et al. [60] used a protocol-driven transfusion strategy (when Hct reached 20%) to compare ANH with conventional blood replacement, finding that ANH reduced the number of patients requiring a transfusion from 36% to 10% (P < 0.05). In a more recent metaanalysis of 42 RCTs in various populations (primarily cardiac, orthopedic, and urinary surgical patients) Segal et al. [58] concluded that ANH was modestly effective, reducing transfusions 10% (on average) or 1-2 units less than the comparator groups. No particular population could be identified in which ANH was more or less effective. Whereas both systematic reviews [58, 59] called for the safety of ANH to be more thoroughly evaluated, in terms of adverse events (Fig. 3) , ANH safety appears similar to comparator groups [58] .
Cell salvage techniques
Intraoperative salvage and retransfusion of shed blood including squeezing blood from sponges and washing with saline for reinfusion are other intraoperative techniques used [25, 28, 29] . Somewhat controversial, salvage procedures have been associated with infection, loss of coagulation factors (if washed), hemolysis, or tumor cell reintroduction [32, 52] . These limitations notwithstanding, cell salvage techniques, when integrated into multimodal blood conservation programs, appear safe and effective [30] .
Pharmacological hemostatic measures
Agents with antifibrinolytic and antiinflammatory properties including aminocaproic acid, aprotinin, desmopressin acetate (DDAVP), tranexamic acid, phytonadione, and vasopressin are used to decrease blood loss and the need for transfusions [26, 61] . Among these, aprotinin is the most extensively studied and exerts hemostasis by both antifibrinolytic and antiinflammatory mechanisms [62, 63] . Safety (thromboembolism, renal complications, and decreased graft patency when combined with antifibrinolytics) and cost are known controversies with aprotinin use [32] . Dramatic reductions in blood usage have been reported using recombinant factor VIIa (rFVIIa) as a hemostatic agent, especially in patients unresponsive to conventional methods [64] [65] [66] [67] . Of concern with rFVIIa is the potential for thrombosis, which has not been observed extensively when used according to its labeled indication, that is, in hemophilia patients with inhibitors to clotting factors [68] . Thromboembolic events have been reported in off-label use, and rFVIIa should be used with caution in patients with high D-dimer levels and consumptive coagulopathy. Isolated cases of anaphylactic and other hypersensitivity reactions have also been reported [69] . As with aprotinin, the cost of rFVIIa is a concern [70 ] . Successful use of pharmacologic agents requires judicious patient evaluation and selection, and policies that reserve highcost therapies for high-risk situations, such as reoperations, complicated and long surgical procedures, or for Jehovah's Witnesses [32] .
Postoperative techniques
Following surgery, vigilant monitoring to detect and arrest bleeding with a swift return to surgery if necessary is key [28, 30] . Phlebotomy frequency and volumes should be minimized [28, 29] . Hypertension is to be avoided and normothermia maintained [28] . Blood salvage techniques and retransfusion of washed blood lost during surgery may be appropriate [32] . Anemia should be treated aggressively and may require a combination of erythropoietic support, proper nutrition, as well as iron (intravenous), folate, and vitamin B 12 replacement [26, 29, 32] .
Applying best practices of bloodless medicine and surgery management to overcome limitations
To accomplish the objectives of bloodless medicine and surgery -that is, blood usage that approaches zero and improves outcomes -an integrated multidisciplinary healthcare team is necessary [29] . Since no single strategy will generally save more than 1 or 2 units of blood, a comprehensive multimodal program such as the one at Englewood Hospital and Medical Center (EHMC) or as described by others [26, 30, 57] should be employed.
Since 1993, the number of RBC units transfused per 'at risk' surgical patient at EHMC has steadily declined (Fig. 4) . In a recent study of patients presenting for cardiac surgery at EHMC, the RBC transfusion rate was 11.1% [25] . This is remarkably low compared with RBC transfusion statistics of 27-92% for CABG patients reported in a survey of 24 centers completed after publication of the National Consensus Guidelines for transfusions [24] . Despite the low transfusion rates at EHMC, mortality and perioperative adverse events matched for illness severity were unaffected [25] .
Highlights of preoperative assessment and planning as described in detail by Martyn et al. [29] and Goodnough et al. [27] are outlined in Table 2 . Predicting transfusion requirements is a critical part of this schema. Factors predicting transfusion risk in orthopedic surgical patients determined in the OSTHEO (Orthopedic Surgery Transfusion Hemoglobin European Overview) study [52] were baseline, preoperative, and postoperative hemoglobin less than 10 g/dl. Participation in an autologous blood donation program reduced the likelihood of transfusions only if the elapsed time for erythropoiesis recovery between donation and surgery was sufficient, thus emphasizing the importance of maintaining perioperative hemoglobin levels and minimizing operative blood losses. The team at EHMC developed and validated a systematic approach to predict transfusion Cardiac ischemia (6) LVD (4) Death (17) MI (15) Number of events per patient in group
Comparator ANH n = number of studies reporting outcomes
Event (n)
Data are from the metaanalysis by Segal et al. [58] . LVD, left ventricular dysfunction; MI, myocardial infarction; VTE, venous thromboembolism.
probability of patients undergoing cardiac surgery based on perioperative risk factors [57] . Six variables [RBC mass, type and urgency of operation, number of diseased vessels, serum creatinine (Cr) ! 1.3 mg/dl, and preoperative prothrombin time (PT)], when used in the equation given in Fig. 5 , may help determine the risk of allogeneic transfusion in a patient about to undergo cardiac surgery.
Conclusion
The goals and objectives of bloodless medicine and surgery programs are to optimize outcomes without having to rely on blood transfusions and, as such, are straightforward but challenging. Overcoming the limitations of any single intervention requires planning, institutional cooperation, and a team committed to excellence with a high regard for patient autonomy. To initiate a bloodless medicine program, institutions should start by monitoring blood product usage and documenting baseline outcomes. As a team is formed and policies are developed and executed, progress in terms of blood usage reduction and outcomes improvement should be tracked over time. This will encourage the institution-wide health of both the program and of patients that are cared for -without blood transfusions.
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